GeneDx Holdings Corp. (NASDAQ:WGS) issued a bullish outlook for 2026 on Monday, forecasting revenue to exceed the half-billion-dollar milestone as the company’s pivot to high-margin exome and genome sequencing gains unprecedented traction.
DexCom (NASDAQ:DXCM) projected its annual revenue will climb toward $5.25 billion in 2026, marking a pivotal year for the glucose-monitoring leader as it phases out older hardware in favor of its longest-lasting sensor technology to date.
AbbVie (NYSE:ABBV) secured exclusive global rights to a novel cancer-fighting antibody from RemeGen Co. on Monday, marking one of the year’s largest oncology licensing agreements as the pharmaceutical giant moves to integrate next-generation bispecifics with its expanding "ADC" platform.
SOPHiA GENETICS (NASDAQ:SOPH) reported a record-breaking performance for 2025, driven by a surge in demand for its AI-powered genomic analysis, as the company prepares for a major leadership transition and moves closer to profitability.
Viking Therapeutics (NASDAQ:VKTX) shares were in focus Monday after the company announced the peer-reviewed publication of its Phase 2 VENTURE study results, reinforcing the weight-loss potential of its lead candidate as it enters a pivotal year of Phase 3 testing.
OneSpaWorld Holdings Limited (NASDAQ:OSW) projected its annual revenue will surpass the $1 billion mark for the first time in 2026, as the company streamlines its global operations to capitalize on a record-breaking surge in cruise ship travel.
Zura Bio Limited 9NASDAQ:ZURA) announced it is expanding the patient population for its mid-stage trial of tibulizumab in hidradenitis suppurativa (HS), a move intended to bolster the study’s statistical power as the company prepares for a critical data readout later this year.
Summit Therapeutics (NASDAQ:SMMT) announced a clinical trial collaboration with GSK (NYSE:GSK) to evaluate the combination of ivonescimab, Summit’s novel investigational PD-1/VEGF bispecific antibody, with risvutatug rezetecan (GSK’227), GSK’s investigational B7-H3-targeting antibody-drug conjugate (ADC), in multiple solid tumor settings, including small cell lung cancer (SCLC).
West Pharmaceutical Services (NYSE:WST), a leading provider of injectable packaging and delivery systems, announced it has entered into a definitive agreement to sell all manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System, along with associated facilities, to AbbVie (NYSE:ABBV) for $112.5 million in cash at closing, subject to customary working capital and other adjustments.
Zymeworks (NASDAQ:ZYME), a clinical-stage biotechnology company developing novel, bispecific antibody therapeutics, provided a strategic update outlining key priorities for 2026, anchored by recent clinical and regulatory progress for its lead candidate Ziihera (zanidatamab-hrii).
Natera (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, released preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2025.
USANA Health Sciences (NYSE:USNA), a global leader in nutritional supplements and wellness products sold through direct selling, today announced preliminary fiscal year 2025 net sales results and its initial net sales outlook for fiscal 2026 ahead of its presentation at the 28th Annual ICR Conference.
